CPSA Europe 2018

Presentation Abstract

Strategies and Perspective on the Impact that Microsampling Techniques Have on Patient Value

John Smeraglia
UCB

Symposium Session 1
Wednesday, February 7
9:45 am - 11:15 am

A range of microsampling techniques have been developed which has resulted in greater focus on how these tools can be utilized to advance knowledge of fundamental pharmacokinetic characteristics in drug development while focusing on value to the patient. Such tools have led to the opportunity to collect blood samples to better understand the fate of noel therapies in a range of population groups where blood sampling maybe difficult to obtain. We plan to outline some of the strategic initiates and learning’s along the path to implementing microsampling in clinical studies which have allowed for robust assessment of Pharmacokinetics while using less invasive techniques which are a real benefit to patients.

About John Smeraglia
John is the Senior Director of Bioanalytical Sciences in Non-Clinical Development at UCB with laboratories in the UK and Belgium. He has responsibilities for bioanalytical sciences to enhance and revolutionise the way that the quantitative bioanalysis is performed from pre-clinical development to post marketing for NBEs and NCEs. He is also responsible for providing bioanalytical leadership for the quantification of mechanistic biochemical biomarkers to advance drug development. John has held bioanalytical leadership positions in the US and EU with innovator drug development companies and CROs. He obtained his first degree in Medical Technology in the US and his second degree in Biomedical Sciences in the UK where his thesis focus on diagnostic markers in the treatment and management of diabetic nephropathy. His has developed his experience in bioanalytical sciences for more than 25 years and is the author of more than 40 peer reviewed publications.